All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

/images/Cortellis_Flagship_Logo_TM_RGB_Color.png
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Artificial intelligence
    • Coronavirus
    • Diagnosing and tracking COVID-19
    • Drugs to Watch 2020
    • The next pandemic
    • Premium reports
      • BioWorld Financings Reports
      • Disease Forecast Reports

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, March 2, 2021
Home » Blogs » BioWorld MedTech Perspectives » On This Date in History: Medicare signed into law in 1965

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

BioWorld MedTech

On This Date in History: Medicare signed into law in 1965

July 30, 2012
By Mark McCarty
No Comments

At the risk of becoming mired in the past, we are inclined to glance backward now and then to see where we’ve been and ask what the past says about where we’re going. So let’s examine July 30, 1965, the date President Lyndon Johnson signed Medicare into law.

As may or may not be widely known, the initial forecast of the cost of Medicare was way off. In 1967, so the story goes, the House Ways and Means Committee guessed that Medicare would aggregately cost roughly $12 billion a year by 1990, a figure that ran fairly close to $110 billion by 1990.

In the intervening years, Congress and others involved in the Medicare policy discussion have perspired heavily over the future of Medicare and Social Security, and the annual Trustee’s report is a great way to find out who listens in on the conversation because they’re the ones who are always wringing their hands.

Rick Foster, the chief actuary at the Centers for Medicare & Medicaid Services predicted in May of last year at an event at the American Enterprise Institute that the Part A trust fund would be gone by 2024, but more recent estimates say 2017 or 2019, depending on whom you ask. Granted the fund is somewhat sensitive to economic conditions, but does anyone really expect a rising economy to balloon it back up to a 2024 expiry?

Lest we become tongue-tied trying to say “Part A trust fund” three times quickly, let’s not forget Part B, the terrain stalked by physicians. Cuts to Medicare spending on Part B imaging have been the norm since the Deficit Reduction Act of 2005, but the consensus now seems to be that this turnip has been bled dry. Squeeze all you want from DME bidding and fraud, but the Part B doc fix (a.k.a., the SGR mess) is still tabulated at $300 billion or better over a decade. You want to find offsets you say? In this fiscal environment?

One possible fix nobody really wants to think about is the use of the word “cost” in the statute that gave rise to Medicare. As many know, the government lost badly in the lawsuit of Hays v. Leavitt, and Hays v. Sebelius didn’t go much better if I’m not mistaken. Would the Independent Payment Advisory Board recommend that Congress allow the Centers for Medicare & Medicaid Services to use cost as a factor in coverage decisions? It’s hard to say, but we do know one thing: That rail has more juice to it than most third rails available to Congress, so only IPAB could get away with even saying such a thing.

So what will become of Medicare in the decades to come if current estimates of its cost are similarly delusional to those bandied about in the early years of the program? I can only guess, but I do know this: If we don’t fix it soon, Generation X will fix it when it finally achieves a majority in Congress. If Medicare is still draining the economy when that day arrives, the fix is nearly certain to be swift and brutal.

You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld

    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus outbreak. Note that we have added three critical tables which are...

  • Today's news in brief

    BioWorld
    BioWorld briefs for March 1.
  • Gloved hand places sample tubes in PCR system

    COVID-19 test makers are adapting for variants

    BioWorld MedTech
    As COVID-19 variants have emerged, so have questions about the effectiveness of tests for infection. While the risk of mutations significantly limiting their...
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech's briefs for March 1.
  • Celltrion-Regkirona-2-9

    Celltrion wins first conditional Korean approval for COVID-19 antibody Regkirona

    BioWorld
    HONG KONG – Celltrion Inc. has received conditional marketing authorization from the Ministry of Food and Drug Safety (MFDS) for its anti-COVID-19 monoclonal...
cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • About
    • Archives
    • Today's news
    • Search BioWorld Science
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
A Clarivate Analytic solution. Link to Clarivate website.
Follow Us

Copyright ©2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing